Enhanced sensitivity to rapamycin following long-term oestrogen deprivation in MCF-7, T-47-D and ZR-75-1 human breast cancer cells

Journal of Endocrinology

Volumn 208, Issue 1, 2011, Pages 21-29

  Ray, Swagat ^a   Fry, Michael J ^a   Darbre, Philippa D ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ESTRADIOL; ESTROGEN; MITOGEN ACTIVATED PROTEIN KINASE; RAPAMYCIN;

ARTICLE; BREAST CANCER; CANCER GROWTH; CELL STRAIN MCF 7; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CELL COUNT; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMONES; CULTURE MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGENS; FLAVONOIDS; HUMANS; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION; SIROLIMUS; TUMOR CELLS, CULTURED;

EID: 78650991752     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1677/JOE-10-0137     Document Type: Article

References (51)

1. Adi S, Wu NY & Rosenthal SM 2001 Growth factor-stimulated phosphorylation of Akt and p70S6K is differentially inhibited by LY294002 and Wortmannin. Endocrinology 142 498-501. (doi:10.1210/en.142.1.498)
2. Akcakanat A, Zhang L, Tsavachidis S & Meric-Bernstam F 2009 The rapamycin-regulated gene expression signature determines prognosis for breast cancer. Molecular Cancer 8 75-85. (doi:10.1186/1476-4598-8-75)
3. Alessi DR, Cuenda A, Cohen P, Dudley DT & Saltiel AR 1995 PD098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. Journal of Biological Chemistry 270 27489-27494. (doi:10.1074/jbc.270.46.27489)
4. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G et al. 2009 Phase II randomised study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. Journal of Clinical Oncology 27 2630-2637. (doi:10.1200/JCO.2008.18.8391)
5. Bernard L, Legay C, Adriaenssens E, Mougel A & Ricort JM 2006 Estradiol regulates the insulin-like growth factor-I (IGFI) signaling pathway: a crucial role for phosphatidylinositol 3-kinase (PI3-kinase) in estrogens requirement for growth of MCF-7 human breast carcinoma cells. Biochemical and Biophysical Research Communications 350 916-921. (doi:10.1016/j.bbrc.2006.09. 116)
6. Carracedo A,Ma L,Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT,T homas G, Kozma SC et al. 2008 Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. Journal of Clinical Investigation 118 3065-3074. (doi:10.1172/JCI34739)
7. Chan CMW, Martin LA, Johnston SRD, Ali S & Dowsett M 2002 Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. Journal of Steroid Biochemistry and Molecular Biology 81 333-341. (doi:10.1016/S0960-0760(02)00074- 2)
8. Chang SB, Miron P, Miron A & Iglehart JD 2007 Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells. Journal of Surgical Research 138 37-44. (doi:10.1016/j.jss.2006.07.003)
9. Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo J, Perou CM, Parker JS, Miller MA, Huntsman DG, Lin L et al. 2009 PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Research 69 3955-3962. (doi:10.1158/0008-5472.CAN-08-4450)
10. Daly RJ & Darbre PD 1990a Cellular and molecular events in loss of estrogen sensitivity in ZR-75-1 and T-47-D human breast cancer cells. Cancer Research 50 5868-5875.
11. Daly RJ & Darbre PD 1990b Interaction of growth factors during progression towards steroid independence in T-47-D human breast cancer cells. Journal of Cellular Biochemistry 43 199-211. (doi:10.1002/jcb.240430302)
12. Darbre PD & Daly RJ 1989 Effects of oestrogen on human breast cancer cells in culture. Proceedings of the Royal Society of Edinburgh 95B 119-132.
13. Darbre P, Yates J, Curtis SA & King RJB 1983 Effect of estradiol on human breast cancer cells in culture. Cancer Research 43 349-354.
14. Di Cosimo S & Baselga J 2008 Targeted therapies in breast cancer: where are we now? European Journal of Cancer 44 2781-2790. (doi:10.1016/j.ejca. 2008.09.026)
15. Dufourney B, Albas J & van Teeffelen AAM 1997 Mitogenic signaling of insulin-like growth factor 1 in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. Journal of Biological Chemistry 272 31163-31171. (doi:10.1074/jbc.272. 49.31163)
16. Ellard SL, Clemons M, Glemon KA, Norris B, Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M et al. 2009 Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC clinical trials group IND.163. Journal of Clinical Oncology 27 4536-4541. (doi:10.1200/JCO.2008.21.3033)
17. Engel LW, Young NA, Tralka TS, Lippman ME, O'Brien SJ & Joyce MJ 1978 Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Research 38 3352-3364.
18. Ghayad SE, Bieche I, Vendrell JA, Keime C, Lidereau R & Dumontet C 2008 mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Science 99 1992-2003. (doi:10.1111/j.1349-7006.2008.00955.x)
19. Hayakawa M, Kawaguchi K, Kaizawa H, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto SF, Parker P et al. 2007 Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110a inhibitors. Bioorganic and Medicinal Chemistry 15 5837-5844. (doi:10.1016/j.bmc.2007.05.070)
20. Herman ME & Katzenellenbogen BS 1994 Alterations in transforming growth factor-α and -β production and cell responsiveness during progression of MCF-7 human breast cancer cells to estrogen-autonomous growth. Cancer Research 54 5867-5874.
21. Isakoff SJ, Engelman JA & Irie HY 2005 Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Research 65 10992-11000. (doi:10.1158/0008-5472.CAN-05-2612)
22. Jeng MH, Shupnik MA, Bender TP, Westin EH, Bandyopadhyay D, Kumar R, Masamura S & Santen RJ 1998 Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 139 4164-4174. (doi:10.1210/en.139.10.4164)
23. Katzenellenbogen BS, Kendra KL, Norman MJ & Berthois Y 1987 Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Research 47 4355-4360.
24. Keydar I, Chen L, Karby S, Weiss FR, Delarea J, Radu M, Chaitcik S & Brenner HJ 1979 Establishment and characterization of a cell line of human breast carcinoma origin. European Journal of Cancer 15 659-670. (doi:10.1016/0014-2964(79)90139-7)
25. Lippman ME & Dickson RB (Eds) 1990 Regulatory Mechanisms in Breast Cancer, pp 1-452. Boston: Kluwer Academic.
26. Lonning PE (Ed.) 2004 Endocrinology and treatment of breast cancer. Clinical Endocrinology and Metabolism 18 1-130.
27. Martin LA, Farmer I, Johnston SRD, Ali S, Marshall C & Dowsett M 2003 Enhanced estrogen receptor (ER) α, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. Journal of Biological Chemistry 278 30458-30468. (doi:10.1074/jbc.M305226200)
28. Martin LA, Pancholi S, Chan CMW, Farmer I, Kimberley C, Dowsett M & Johnston SRD 2005 The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signaling. Endocrine-Related Cancer 12 1017-1036. (doi:10.1677/erc.1.00905)
29. Masamura S, Santner SJ, Heitjan DF & Santen RJ 1995 Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. Journal of Clinical Endocrinology and Metabolism 80 2918-2925. (doi:10.1210/jc.80.10.2918)
30. Miller WR 1996 Estrogen and Breast Cancer, pp 1-203. London: Chapman and Hall.
31. Murphy CS, Meisner LF, Wu SQ & Jordan VC 1989 Short- and long-term estrogen deprivation of T47D human breast cancer cells in culture. European Journal of Cancer and Clinical Oncology 25 1777-1788. (doi:10.1016/0277-5379(89) 90348-9)
32. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL et al. 2006 mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Research 66 1500-1508. (doi:10.1158/0008-5472.CAN-05-2925)
33. Osborne CK, Hobbs K & Trent JM 1987 Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Research and Treatment 9 111-121. (doi:10.1007/BF01807363) (Pubitemid 17114724)
34. Sabnis GJ, Jelovac D, Long B & Brodie A 2005 The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Research 65 3903-3910. (doi:10.1158/0008-5472.CAN- 04-4092)
35. Sadler TM, Gavriil M, Annable T, Frost P, Greenberger LM & Zhang Y 2006 Combination therapy for treating breast cancer using antiestrogen, ER-923, and the mammalian target of rapamycin inhibitor, temsirolimus. Endocrine-Related Cancer 13 863-873. (doi:10.1677/erc.1.01170)
36. Santen R, Jeng MH & Wang JP 2001 Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology 79 115-125. (doi:10.1016/S0960-0760(01)00151-0)
37. Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura S, Lawrence J Jr, MacMahon LP, Yue W & Berstein L 2005 Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. Journal of Steroid Biochemistry and Molecular Biology 95 155-165. (doi:10.1016/j.jsbmb.2005.04.025)
38. Santen RJ, Song RX, Masamura S, Yue W, Fan P, Sogon T, Hayashi S, Nakachi K & Eguchi H 2008 Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells. Advances in Experimental Medicine and Biology 630 19-34.
39. Shaw LE, Sadler AJ, Pugazhendhi D & Darbre PD 2006 Changes in oestrogen receptor-α and -β during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 99 19-32. (doi:10.1016/j.jsbmb.2005.11.005)
40. Shim WS, Conaway M & Masamura S 2000 Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 141 396-405. (doi:10.1210/en.141.1. 396)
41. Staka CM, Nicholson RI & Gee JMW 2005 Acquired resistance to oestrogen deprivation: role for growth factor signaling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model. Endocrine-Related Cancer 12 S85-S97. (doi:10.1677/erc.1.01006)
42. Stephen RL, Shaw LE, Larsen C, Corcoran D & Darbre PD 2001 Insulin-like growth factor receptor levels are regulated by cell density and by long-term estrogen deprivation in MCF7 human breast cancer cells. Journal of Biological Chemistry 276 40080-40086. (doi:10.1074/jbc.M105892200)
43. Treeck O, Wackwitz B, Haus U & Ortmann O 2006 Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecologic Oncology 102 292-299. (doi:10.1016/j.ygyno.2005.12.019)
44. Vlahos CJ, Matter WF, Hui KY & Brown RF 1994 A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). Journal of Biological Chemistry 269 5241-5248.
45. Weinstein IB & Joe A 2008 Oncogene addiction. Cancer Research 68 3077-3080. (doi:10.1158/0008-5472.CAN-07-3293)
46. Welshons WV & Jordan VC 1987 Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. European Journal of Cancer and Clinical Oncology 23 1935-1939. (doi:10.1016/0277-5379(87)90062-9)
47. Wullschleger S, Loewith R & Hall MN 2006 TOR signaling in growth and metabolism. Cell 124 471-484. (doi:10.1016/j.cell.2006.01.016)
48. Yamnik RL, Digilova A, Davis DC, Brodt ZN, Murphy CJ & Holz MK 2009 S6 kinase 1 regulates estrogen receptor α in control of breast cancer cell proliferation. Journal of Biological Chemistry 284 6361-6369. (doi:10.1074/jbc.M807532200)
49. Yue W, Wang JP, Conaway M, Masamura S, Li Y & Santen RJ 2002 Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol. Endocrinology 143 3221-3229. (doi:10.1210/en.2002-220186)
50. Yue W, Wang JP, Conaway MR, Li Y & Santen RJ 2003 Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways. Journal of Steroid Biochemistry and Molecular Biology 86 265-274. (doi:10.1016/S0960-0760(03)00366-2)
51. Yue W, Wang J, Li Y, Fan P & Santen RJ 2005 Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells. International Journal of Cancer 117 746-754. (doi:10.1002/ijc.21222)